Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Free Vaccine Clear all
Completed Not applicable Interventional Accepts healthy volunteers

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility

NCT02975596
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
Awareness, Education, Empowerment, Accessibility
Other
Lead sponsor
University of Florida
Other
Eligibility
16 Years to 99 Years
Enrollment
1,326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
6
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

NCT02914275
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 59 Months
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Not applicable Interventional Results available

Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma

NCT00597272
View directory record Official record
Conditions
Melanoma
Interventions
KLH conjugates with GD2L and GD3L
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

NCT00955006
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

NCT00680147
View directory record Official record
Conditions
HPV
Interventions
brief informational intervention to promote HPV vaccine acceptance
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
11 Years and older
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

NCT00001088
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, Bupivacaine hydrochloride
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Message Offering Free Round Trip Ride-Share Ride to Pharmacy

NCT05612373
View directory record Official record
Conditions
COVID-19
Interventions
COVID Booster text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

NCT00587249
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Malaria ICC-1132, Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS

NCT04333459
View directory record Official record
Conditions
Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Interventions
Hantaan DNA Vaccine/Puumala DNA Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 2, 2026, 11:01 AM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.

NCT04646616
View directory record Official record
Conditions
Covid19, Mental Health Issue, Violence
Interventions
Community popular opinion leader (POL) based intervention
Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

NCT03879694
View directory record Official record
Conditions
Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
Interventions
Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Messaging for Vaccination

NCT05182554
View directory record Official record
Conditions
Vaccination Refusal, COVID-19 Pandemic
Interventions
Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

NCT04142086
View directory record Official record
Conditions
Yellow Fever (Healthy Volunteers)
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine, Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 2, 2026, 11:01 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

NCT04942210
View directory record Official record
Conditions
Yellow Fever, Healthy Volunteers
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
11
States / cities
Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus QIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 17 Years
Enrollment
2,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Madera, California • Ontario, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 2, 2026, 11:01 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Human Immune Response to Ixodes Scapularis Tick Bites

NCT05036707
View directory record Official record
Conditions
Tick-borne Diseases, Tick Resistance, Lyme Disease
Interventions
Xenodiagnosis Ticks, skin biopsy, blood draw
Device · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350
View directory record Official record
Conditions
Healthy Adults
Interventions
LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
Device · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A School Health Center Intervention to Increase Adolescent Vaccination

NCT01595542
View directory record Official record
Conditions
Immunization Program, School Health Services, HPV Vaccines
Interventions
Modified Vaccine Consent Form
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
3,417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 2, 2026, 11:01 AM EDT
Completed Phase 4 Interventional

HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

NCT04474821
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Educational Intervention, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 2, 2026, 11:01 AM EDT